Press Releases

Sente, Inc. Announces the Appointment of Michael York as President and Chief Executive Officer

SAN DIEGO, Jul 11, 2013 (GLOBE NEWSWIRE) — Sente, Inc., a privately held cosmeceutical company engaged in the development of differentiated skincare products based on glycoproteins, announced today the appointment of Michael York as President, Chief Executive Officer and a member of the Board of Directors. Mr. York joins Sente after more than 20 years in management and leadership positions at Amylin Pharmaceuticals, Santarus, Inc., Amgen and AstraZeneca.

“We are delighted to welcome Mr. York, a well respected commercial leader in the healthcare industry, as President and CEO of Sente. His strategic vision and extensive experience in healthcare operations, marketing and finance, will make him an invaluable member of the Sente team,” said Faheem Hasnain, Chairman of the Board of Directors of Sente, Inc. “We are confident that under his leadership, Sente will be well positioned to take advantage of the fast growing cosmetic market, and allow the company to emerge as a major contender in the space.”

“I am pleased to lead Sente and its experienced team through this crucial period of company growth. Our goal is to leverage the broad utility of heparan sulfate to build a leading global dermatologic franchise,” said Mr. York. “Our near-term priorities are focused on further positioning Sente Dermal Repair Cream with dermatologists, building a commercial team in the U.S and selecting partners to commercialize the Sente portfolio outside of the U.S.”

Mr. York brings to Sente more than 20 years of management, commercial and finance experience in the biopharmaceutical industry, including leadership positions in sales, marketing, pricing, managed care, commercial operations, and investor relations at early stage and global life sciences companies.

Most recently, Michael was Vice President, Sales and Marketing for the Specialty and Rare Disease Business Unit at Amylin Pharmaceuticals where he was responsible for leading worldwide development and commercialization of Amylin products and pipeline assets in the endocrine specialty market. Prior to this role, Michael served as Senior Director of Investor Relations at Amylin and held responsibility for managing the financial global brand. Michael has significant experience in developing relationships with U.S. and European equity analysts and investment bankers along with attracting and retaining long-term investors, including mutual funds and hedge funds. Michael holds a BA degree in Public Administration and Economics from San Diego State University and a MBA degree from the University of Redlands.

About Sente, Inc.

Sente, Inc., a privately held specialty aesthetics company, is a recognized leader in the development of innovative and targeted skincare products utilizing HSA technology, a low molecular weight formulation of heparan sulfate. HSA is essential for skin hydration, rejuvenation and necessary for healthy-looking skin. Sente was founded in 2007 and is based in San Diego, California. Further information may be found at https://sentelabs.com/. Sente products are available through an exclusive network of physicians, medically supervised spas.

SENTÉ Press Contact:

Creative Media Marketing
sente@cmmpr.com
(212) 979-8884

Leave a Reply

Your email address will not be published.